Is Celgene’s Juno Deal a Boon or a Boondoggle?
June 30, 2015 at 10:43 AM EDT
The $1 billion drug development partnership biotech giant Celgene (CELG) unveiled yesterday with Juno Therapeutics (JUNO) is doing great things for investors in the fledgling drug maker, sending the stock soaring 20% in morning market action. It’s not hard to see why. The 10-year deal has Celgene placing a big bet on the startup, paying [...]
